| Index | — | P/E | — | EPS (ttm) | -1.07 | Insider Own | 38.38% | Shs Outstand | 197.23M | Perf Week | 9.66% |
| Market Cap | 694.25M | Forward P/E | — | EPS next Y | -1.30 | Insider Trans | -0.03% | Shs Float | 165.32M | Perf Month | -6.88% |
| Enterprise Value | 302.25M | PEG | — | EPS next Q | -0.33 | Short Float | 12.80% | Perf Quarter | -41.33% | ||
| Income | -210.00M | P/S | 9.92 | EPS this Y | — | Short Ratio | 6.67 | Perf Half Y | -52.88% | ||
| Sales | 70.00M | P/B | 1.73 | EPS next Y | — | ROA | -41.45% | Short Interest | 21.17M | Perf YTD | -79.29% |
| Book/sh | 2.04 | P/C | 1.61 | EPS next 5Y | — | ROE | -44.48% | 52W High | 21.73 -83.80% | Perf Year | -57.59% |
| Cash/sh | 2.19 | P/FCF | — | EPS past 3/5Y | — | ROIC | -49.75% | 52W Low | 3.04 15.79% | Perf 3Y | -36.23% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | 120.70% 16.54% | Gross Margin | 96.81% | Volatility | 8.65% 5.90% | Perf 5Y | -20.00% |
| Dividend TTM | — | EV/Sales | 4.32 | EPS Y/Y TTM | — | Oper. Margin | -320.94% | ATR (14) | 0.23 | Perf 10Y | -88.32% |
| Dividend Ex-Date | — | Quick Ratio | 8.38 | Sales Y/Y TTM | -36.36% | Profit Margin | -296.86% | RSI (14) | 46.63 | Recom | 2.04 |
| Dividend Gr. 3/5Y | — | Current Ratio | 8.38 | EPS Q/Q | 6.25% | SMA20 | 4.53% | Beta | -1.45 | Target Price | 12.33 |
| Payout | 0.00% | Debt/Eq | 0.10 | Sales Q/Q | 62.50% | SMA50 | -12.66% | Rel Volume | 0.59 | Prev Close | 3.59 |
| Employees | 317 | LT Debt/Eq | 0.10 | Earnings | Feb 25 | SMA200 | -52.25% | Avg Volume | 3.30M | Price | 3.52 |
| IPO Date | Nov 11, 2015 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 8.83% 191.60% | Net Debt/EBITDA | — | Volume | 1,941,203 | Change | -1.95% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-27-26 | Reiterated | Leerink Partners | Outperform | $12 → $10 |
| Oct-15-26 | Initiated | UBS | Buy | $13 → $11 |
| Oct-02-26 | Reiterated | Wedbush | Outperform | $12 → $13 |
| Sep-23-26 | Downgrade | JP Morgan | Overweight → Neutral | |
| Aug-03-26 | Reiterated | UBS | $32 → $13 | |
| Jul-31-26 | Reiterated | Wedbush | Outperform | $33 → $12 |
| Jun-11-26 | Reiterated | New Street | $13 | |
| May-20-26 | Reiterated | Wells Fargo | Overweight | $13 → $14 |
| May-19-26 | Reiterated | HC Wainwright & Co. | Buy | $18 → $13 |
| Apr-29-26 | Reiterated | Truist Securities | Buy | $15 |
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 70 | 43 | 108 | 113 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 2 | 9 | 0 | 0 | — | — | — | — | — | |
| Gross Profit | 68 | 34 | 108 | 113 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 93 | 75 | 59 | 51 | — | — | — | — | — | |
| Research and Development | 205 | 183 | 160 | 130 | — | — | — | — | — | |
| Other Operating Expense | -2 | -9 | 0 | 0 | — | — | — | — | — | |
| Operating Income | -227 | -215 | -110 | -68 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 16 | 11 | 13 | 10 | — | — | — | — | — | |
| Net Income Before Taxes | -210 | -204 | -97 | -58 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | -1 | — | — | — | — | — | |
| Consolidated Net Income | -210 | -204 | -97 | -58 | — | — | — | — | — | |
| Net Income From Continuing Operations | -210 | -204 | -97 | -58 | — | — | — | — | — | |
| Net Income | -210 | -204 | -97 | -58 | — | — | — | — | — | |
| EPS (Recurring) | -1.07 | -1.21 | -0.70 | -0.54 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.07 | -1.21 | -0.70 | -0.54 | — | — | — | — | — | |
| EPS (Diluted) | -1.07 | -1.21 | -0.70 | -0.54 | — | — | — | — | — | |
| EBITDA | -206 | -196 | -88 | -49 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 10.26 | 66.81 | 15.81 | 4.74 | — | — | — | — | — | |
| Gross Margin | 97.14 | 79.07 | 100.00 | 100.00 | — | — | — | — | — | |
| Operating Margin | -324.29 | -500.00 | -101.85 | -60.18 | — | — | — | — | — | |
| Net Margin | -300.00 | -474.42 | -89.81 | -51.33 | — | — | — | — | — | |
| Shares Outstanding | 204 | 169 | 138 | 106 | — | — | — | — | — | |
| Market Capitalization | 718 | 2,873 | 1,707 | 535 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Rawcliffe Adrian | Director | Aug 12 '26 | Sale | 5.29 | 12,700 | 67,183 | 0 | Aug 13 |
| TAKANASHI KEN | Director | Aug 11 '26 | Sale | 6.01 | 3,864 | 23,223 | 20,079 | Aug 13 |
| Wagner Heidi L | Director | Aug 11 '26 | Option Exercise | 5.97 | 7,000 | 41,790 | 51,930 | Aug 13 |
| Wagner Heidi L | Director | Aug 11 '26 | Sale | 6.01 | 7,000 | 42,070 | 44,930 | Aug 13 |
| Tan Aik Na | Director | Aug 11 '26 | Sale | 6.01 | 432 | 2,596 | 24,968 | Aug 13 |
| RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Mar 30 '26 | Buy | 6.50 | 971,091 | 6,312,092 | 26,975,505 | Mar 30 |
| RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Mar 27 '26 | Buy | 6.43 | 2,495,623 | 16,046,856 | 26,004,414 | Mar 30 |
| RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Mar 26 '26 | Buy | 6.08 | 5,305,782 | 32,265,430 | 23,508,791 | Mar 30 |
| Francis Chris | Officer | Feb 26 '26 | Sale | 15.05 | 33,194 | 499,593 | 61,867 | Feb 27 |
| Francis Chris | Officer | Feb 26 '26 | Option Exercise | 4.28 | 33,194 | 141,920 | 79,767 | Feb 27 |
| Moran Kyle | Chief Financial Officer | Feb 09 '26 | Sale | 13.45 | 3,588 | 48,259 | 134,385 | Feb 11 |
| BOLNO PAUL | President and CEO | Feb 09 '26 | Sale | 13.45 | 10,480 | 140,956 | 275,520 | Feb 11 |
| Vargeese Chandra | Officer | Feb 09 '26 | Sale | 13.45 | 3,228 | 43,417 | 408,246 | Feb 11 |
| Francis Chris | Officer | Feb 09 '26 | Sale | 13.45 | 1,883 | 25,326 | 61,867 | Feb 11 |
| Francis Chris | Officer | Jan 02 '26 | Option Exercise | 3.14 | 9,375 | 29,438 | 34,375 | Jan 06 |